Only three out of ten MPAS genes (PHLDA1, EPHA2, and DUSP4) displayed reproducible associations with baseline levels and changes in MEK/ERK activity across most ovarian cancer model systems and clinical samples. This evidence concerns the gene EPHA2 and ovarian carcinoma.